Pembrolizumab

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cutaneous T Cell Lymphoma

Conditions

Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome

Trial Timeline

Jan 15, 2019 → Sep 1, 2025

NCT ID

NCT03385226

About Pembrolizumab

Pembrolizumab is a phase 2 stage product being developed by Merck for Cutaneous T Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03385226. Target conditions include Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02083484	Pre-clinical	Completed	—	—	Melanoma
NCT07302347	Phase 1/2	Recruiting	Mar 31, 2026	Dec 31, 2029	Malignant Neoplasm
NCT07089992	Phase 2	Recruiting	Dec 4, 2025	Dec 1, 2028	Sarcoma
NCT07007273	Phase 2	Recruiting	Jun 20, 2025	Jul 1, 2030	Cutaneous Sarcoma
NCT04569461	Phase 2	Withdrawn	Jun 1, 2025	Dec 1, 2026	Prostate Cancer
NCT05815927	Phase 3	Recruiting	May 23, 2025	Mar 30, 2030	Oligometastatic Squamous Cell Carcinoma of the Head and Neck
NCT05852223	Phase 2	Recruiting	Dec 20, 2024	Dec 1, 2027	Differentiated Thyroid Cancer
NCT05879120	Phase 2	Withdrawn	Jul 30, 2024	Oct 2, 2024	Recurrent Glioblastoma
NCT06004336	Phase 2	Recruiting	Oct 31, 2023	Jan 1, 2029	Oligometastatic Renal Cell Carcinoma
NCT05496036	Phase 2	Recruiting	Feb 13, 2023	Sep 30, 2027	Merkel Cell Carcinoma
NCT05131919	Phase 2	Active	Dec 22, 2022	Jul 1, 2031	Colorectal Cancer
NCT05197322	Phase 2	Recruiting	Jul 20, 2022	Dec 1, 2028	Adenocarcinoma of the Colon
NCT05406713	Phase 2	Active	Jul 13, 2022	Jan 1, 2028	Muscle Invasive Bladder Carcinoma
NCT05025813	Phase 2	Recruiting	Jun 28, 2022	Jun 1, 2027	Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT06413095	Phase 1	Completed	Jun 1, 2022	Jun 22, 2023	Head and Neck Squamous Cell Carcinoma
NCT05191472	Phase 2	Terminated	May 3, 2022	Dec 31, 2023	Multiple Myeloma
NCT05204160	Phase 2	Withdrawn	Apr 11, 2022	Feb 27, 2024	Plasma Cell Myeloma
NCT04575961	Phase 2	Active	Feb 22, 2022	Mar 1, 2028	Ovarian Cancer
NCT04417166	Phase 2	Recruiting	Feb 11, 2022	Dec 1, 2026	Lymphoma, Extranodal NK-T-Cell
NCT05188508	Phase 2	Recruiting	Jan 14, 2022	Jan 1, 2027	Glioma

Competing Products

20 competing products in Cutaneous T Cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
ONTAK (denileukin difitox, DAB389IL-2)	Eisai	Approved	85
ONTAK	Eisai	Approved	85
E7777 9 mcg/kg	Eisai	Phase 3	77
ONTAK	Eisai	Approved	85
Mogamulizumab	Kyowa Kirin	Approved	85
Mogamulizumab + Brentuximab vedotin	Kyowa Kirin	Phase 1	33
Mogamulizumab	Kyowa Kirin	Phase 2	52
KW-0761 + Vorinostat	Kyowa Kirin	Phase 3	77
Enzastaurin	Eli Lilly	Phase 2	52
Clopidogrel + Ticagrelor	AstraZeneca	Approved	85
Pembrolizumab	Merck	Phase 2	52
Comparator: vorinostat	Merck	Pre-clinical	23
TR701 FA	Merck	Phase 2	52
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Tulisokibart + Placebo	Merck	Phase 2	52
Aspirin + Ipilimumab + Pembrolizumab	Merck	Phase 2	52
Pembrolizumab + Mogamulizumab	Merck	Phase 2	52
TR-701 FA + Linezolid	Merck	Phase 3	77
Pimasertib + Dacarbazine	Merck	Phase 2	52

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved